Search results
Results from the WOW.Com Content Network
Rivaroxaban was patented in 2007 and approved for medical use in the United States in 2011. [10] It is available as a generic medication. [11] It is on the World Health Organization's List of Essential Medicines. [12] In 2022, it was the 90th most commonly prescribed medication in the United States, with more than 7 million prescriptions. [13] [14]
Antistasin, the first discovered naturally occurring direct Xa inhibitor Rivaroxaban, the first synthetic direct Xa inhibitor marketed as a drug Prior to the introduction of direct factor Xa inhibitors, vitamin K antagonists such as warfarin were the only oral anticoagulants for over 60 years, and together with heparin have been the main blood ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The FDA has given Johnson & Johnson (NYS: JNJ) the green light to market Xarelto to prevent stroke among patients suffering from atrial fibrillation -- opening up a blockbuster market involving ...
It took nine months since Novartis (NVS) published results from a late-stage study of its multiple sclerosis pill, but the Swiss pharmaceutical finally announced Wednesday that the U.S. Food and ...
AstraZeneca (AZN) announced that it failed to win the approval of the U.S. Food and Drug Administration for its heart drug Brilinta, a blood-thinner that the company -- facing a severe patent ...
Drug Main indication Trade name 2015 2016 ... rivaroxaban: anticoagulant: Xarelto 6589 6234 12 ... First Approval Date Patent Expiration Date [6] [7] 1:
(not approved) (many companies) Yes Generics, e.g., Duovir-N: lamivudine zidovudine: nevirapine (not approved) (many companies) Yes Truvada: emtricitabine tenofovir disoproxil: August 2, 2004 Gilead Sciences: No Atripla: emtricitabine tenofovir disoproxil efavirenz: July 12, 2006 Gilead Sciences Bristol-Myers Squibb: Yes Complera (US) Eviplera ...